STUDY OF LONG-TERM EFFECTIVENESS OF THREE INITIAL HAART STRATEGIES IN HIV PTS

三种初始 HAART 策略治疗 HIV PTS 的长期有效性研究

• 批准号: 7376245
• 负责人: DAVID M MUSCHATT
• 金额: $ 5.96万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376245
• 关键词: STUDY; LONG; TERM; EFFECTIVENESS; THREE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the FIRST (Flexible Initial Retrovirus Suppressive Therapies) study is to determine whether it is better to start antiretroviral (AR) treatment with a protease inhibitor (PI) containing regimen, a non-nucleoside reverse transcriptase inhibitor (NNRTI) containing regimen, or a PI plus NNRTI containing regimen in PI- and NNRTI-naive, HIV-infected individuals. An important feature of this study is that the specific AR drugs used in each of the three drug regimens and those used after initial virologic failure are left to the discretion of each patient's clinician. The study also includes two randomized substudies that will assign PI(s) and/or the NNRTI. This study will compare the impact of the three HAART strategies on long-term plasma HIV RNA levels and future AR treatment options over an anticipated study duration of 60 months. While the primary aim of this study is to rank order the effectiveness of the three HAART strategies, the planned secondary analyses will permit an improved understanding of reasons for differences in effectiveness.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。 FIRST（灵活初始逆转录病毒抑制疗法）研究的目的是确定对于未接受过 PI 和 NNRTI 治疗的 HIV 感染者，使用含有蛋白酶抑制剂 (PI) 的方案、含有非核苷逆转录酶抑制剂 (NNRTI) 的方案或含有 PI 加 NNRTI 的方案开始抗逆转录病毒 (AR) 治疗是否更好。这项研究的一个重要特点是，三种药物方案中使用的具体 AR 药物以及最初病毒学失败后使用的药物由每位患者的临床医生自行决定。该研究还包括两项分配 PI 和/或 NNRTI 的随机子研究。 本研究将比较三种 HAART 策略对长期血浆 HIV RNA 水平和未来 AR 治疗方案的影响，预计研究持续时间为 60 个月。虽然本研究的主要目的是对三种 HAART 策略的有效性进行排序，但计划进行的二次分析将有助于更好地理解有效性差异的原因。